摘要
分化型甲状腺癌（DTC）在经过手术、放射性碘治疗、甲状腺激素抑制治疗后，仍需终身随诊。目前DTC的日常随诊方法如常规影像学方法、甲状腺球蛋白测定和131I全身显像仍有其不足之处，临床上常常发现一些患者存在不摄碘的失分化病灶，定位这些失分化的病灶，对确定患者的进一步治疗至关重要。肿瘤阳性显像剂。99Tcm-甲氧基异丁基异腈（99Tcm-MIBI），由于其良好的物理和剂量测量方面的特性，价格便宜，国内外对其在DTC随访中的作用做了大量基础及临床研究。本综述主要从原理、显像方法、显像结果分析、优势介绍99Tcm-MIBI显像在DTC随访的应用。
Patient suffered from differentiated thyroid carcinoma （DTC） needs lifetime follow-up even after going through the thyroidectomy, postoperative 131I treatment, thyroid stimulating hormone suppressing therapy. There are disadvantages in DTC routine follow-up, such as conventional radiological studies, measurement of serum thyroglobulin and 131I scintigraphy. It is not rare for us to see patients with dedifferentiated metastases which with no radioiodine uptake, and how to locate these dedifferentiated metastases is of great importance for making further treatment plan. Tumor imaging agent 99Tcm- methoxyisobutylisonitrile （99Tcm-MIBI） is widely used in the clinical and laboratories research of DTC in domestic and overseas, for its excellent physical and dosimetric characteristics and reasonable price. This review relates the application of 99Tcm-MIBI imaging in DTC follow-up, and focuses on its imaging mechanism, clinical methods, imaging interpretation, and the advantages.
出处
《国际放射医学核医学杂志》
2009年第5期275-278,共4页
International Journal of Radiation Medicine and Nuclear Medicine
